Moffitt Cancer Center Researchers Target Specific Protein Associated with Poor Survival and Treatment Resistance in Brain Cancer Patients
With highly aggressive brain tumors come low survival rates. Glioblastoma multiforme (GBM) gives newly diagnosed patients a median of 14 months to live while recurring patients a median of only three to nine months. Because of this, new therapeutic targets and biomarkers for better prognosis is urgently needed. Recently, researchers from the Moffitt Cancer Center reported that the expression of the BIRC3 protein is linked to poor survival and recurrence of the disease in patients. This may indicated a good therapeutic target. For patients, standard treatment of GBM is chemotherapy and radiation. These treatments can be effective for a period of time, but most will see a recurrence in the tumor and disease. To read more about their findings, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada